Jefferies analyst Peter Welford downgraded GSK (GSK) to Hold from Buy with a price target of $39.50, down from $53. The firm ...

Jefferies said it still regards GSK’s fundamental value as “compelling,” adding that its 2027+ estimates for sales and ...

The drugmaker’s U.S. plans comes on the heels of a rough quarter, with lower vaccine demand driving down Q3 sales by 15% year ...

GSK managed to beat analysts’ revenue predictions ... driven once again by its shingles vaccine Shingrix and HIV therapies sold under the ViiV Healthcare joint venture. Shingrix grew 19% to ...

GSK says following the FDA approval, it will await the recommendation from ACIP before launching the product in the US. Key to Shingrix's success will be whether the US CDC decides to switch from ...

GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of UK-based GSK Plc., a global biopharma ... In 2022-23, the Company launched Shingrix, a vaccine for prevention of herpes zoster (HZ ...

Sherman Yu, GSK Vice President and GSK China General Manager ... In the vaccines area, highlights include Shingrix, which is a recombinant shingles vaccine that combines antigens and adjuvant systems ...

The print ads featured a prominent display of a person’s back, highlighting where shingles rashes typically emerge.

At the Financial Times (FT) Global Pharma and Biotech Summit in London on 6 November, GSK CEO Emma Walmsley addressed these concerns and underscored the critical role of the US in GSK’s operations.

Teva Pharmaceutical Industries Ltd. ADR-2.23% $19.91B ...

Company has Deloitte Haskins & Sells LLP as its auditors. As on 30-06-2024, the company has a total of 16.94 Crore shares outstanding.GSK Pharma Share Price Today is Rs. 2539.30 as on 11 Nov, 2024, 03 ...